Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA

Samir S. Taneja

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA'. Together they form a unique fingerprint.